The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
about
The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The long-term pharmacokinetics ...... imen in HIV-infected patients.
@en
The long-term pharmacokinetics ...... imen in HIV-infected patients.
@nl
type
label
The long-term pharmacokinetics ...... imen in HIV-infected patients.
@en
The long-term pharmacokinetics ...... imen in HIV-infected patients.
@nl
prefLabel
The long-term pharmacokinetics ...... imen in HIV-infected patients.
@en
The long-term pharmacokinetics ...... imen in HIV-infected patients.
@nl
P2093
P2860
P1433
P1476
The long-term pharmacokinetics ...... imen in HIV-infected patients.
@en
P2093
Andersen AB
Gerstoft J
Klitgaard NA
Mathiesen LR
Pedersen C
P2860
P304
P356
10.1111/J.1468-1293.2005.00317.X
P577
2005-09-01T00:00:00Z